Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.